DA
IONS icon

DCF Advisers’s Ionis Pharmaceuticals IONS Stock Holding History

DCF Advisers’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,500
Closed -$45.3K – 87
2025
Q1 		$45.3K Buy
+1,500
New +$49.1K 0.02% 83

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Tweedy, Browne Co
Tweedy, Browne Co Stamford, Connecticut $1.23B AUM 16.54% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
GW&K Investment Management
GW&K Investment Management Boston, Massachusetts $11.8B AUM 29.45% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

DCF Advisers's IONS Position: Q3 2026 in Review

DCF Advisers increased its Ionis Pharmaceuticals (IONS) stake by 2.7% in Q3 2026, buying an estimated $56.8K and bringing the position to 38,500 shares worth $1.72M. The position accounts for 0.39% of the portfolio, ranked #53.

DCF Advisers first reported a position in IONS in Q2 2024 and has held it in 10 quarters since. The position peaked at $8.15M in Q4 2025. 227 funds tracked by Wall St. Rank hold IONS as of Q3 2026.

  • DCF Advisers held 38,500 shares of Ionis Pharmaceuticals worth $1.72M as of Q3 2026.
  • DCF Advisers bought 1,000 Ionis Pharmaceuticals shares in Q3 2026, an estimated $56.8K.
  • Ionis Pharmaceuticals made up 0.39% of DCF Advisers's portfolio in Q3 2026, its #53 holding.
  • DCF Advisers first reported a position in Ionis Pharmaceuticals in Q2 2024 and has held it in 10 quarters since.
  • DCF Advisers's Ionis Pharmaceuticals position peaked at $8.15M in Q4 2025.
  • 227 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2026.

Based on DCF Advisers's 13F filing for Q3 2026, filed 4 Nov 2026.